Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study

Détails

ID Serval
serval:BIB_CBC01EB0C9AB
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study
Périodique
Lancet
Auteur(s)
Fellay  J., Boubaker  K., Ledergerber  B., Bernasconi  E., Furrer  H., Battegay  M., Hirschel  B., Vernazza  P., Francioli  P., Greub  G., Flepp  M., Telenti  A.
ISSN
0140-6736 (Print)
Statut éditorial
Publié
Date de publication
2001
Volume
358
Numéro
9290
Pages
1322-1327
Langue
anglais
Notes
Journal Article Research Support, Non-U.S. Gov't --- Old month value: Oct 20
Résumé
BACKGROUND: Data on adverse events to antiretroviral treatment have been recorded in clinical trials, post-marketing analyses, and anecdotal reports. Such data might not be an up-to-date or comprehensive assessment of all possible treatment combinations defined as potent antiretroviral treatment. METHODS: Using a standard clinical and laboratory method, we assessed prevalence of adverse events in 1160 patients who were receiving antiretroviral treatment. We measured the toxic effects associated with the drug regimen (protease inhibitor [PI], non-nucleoside and nucleoside analogue reverse transcriptase inhibitor) and specific compounds using multivariate analyses. FINDINGS: 47% (545 of 1160) of patients presented with clinical and 27% (194 of 712) with laboratory adverse events probably or definitely attributed to antiretroviral treatment. Among these, 9% (47 of 545) and 16% (30 of 194), respectively, were graded as serious or severe. Single-PI and PI-sparing-antiretroviral treatment were associated with a comparable prevalence of adverse events. Compared with single-PI treatment, use of dual-PI-antiretroviral treatment and three-class-antiretroviral treatment was associated with higher prevalence of adverse events (odds ratio [OR] 2.0 [95% CI 1.0-4.0], and 3.9 [1.2-12.9], respectively). Compound specific associations were identified for zidovudine, lamivudine, stavudine, didanosine, abacavir, ritonavir, saquinavir, indinavir, nelfinavir, efavirenz, and nevirapine. INTERPRETATION: We recorded a high prevalence of toxic effects attributed to antiretroviral treatment for HIV-1. Such data provides a reference for regimen-specific and compound-specific adverse events and could be useful in postmarketing analyses of toxic effects.
Mots-clé
Adult Anti-HIV Agents/*adverse effects Cross-Sectional Studies Female Humans Logistic Models Male Middle Aged Prevalence Prospective Studies Reverse Transcriptase Inhibitors/*adverse effects Severity of Illness Index Switzerland/epidemiology
Pubmed
Web of science
Création de la notice
25/01/2008 18:08
Dernière modification de la notice
20/08/2019 16:46
Données d'usage